Results 71 to 80 of about 15,511 (169)

Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 914-929, October 2026.
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg, José M.A. Moreira   +1 more
wiley   +1 more source

Possible mechanisms underlying abacavir-related cardiovascular complications

, 2010
Abacavir is a nucleoside reverse transcriptase inhibitor commonly used for the treatment of HIV infection. However, several clinical studies indicated that patients receiving abacavir treatment were connected to an increase in cardiovascular risks. Since
Li, WS, Leung, GPH, Kwan, YW
core   +1 more source

Integrative omics in translational pharmacology: A target‐credibility framework for biomarker‐guided therapy

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Integrative omics strengthens target credibility by combining causal, functional, pharmacological and tissue‐context evidence. Go, refine and stop decisions convert multi‐omics findings into actionable translational choices. Biomarker readiness requires analytical validity, clinical validity, utility and implementation within a defined context of use ...
Ruba Altahla, Zhaowei Wang, Shan‐Jie Rong, Chaoyi Li, Nasir Jadgal, Mohammad Javad Mehran, Mansoor Bolideei, Jamal Alshorman   +7 more
wiley   +1 more source

Global “expiration” of abacavir in adults with HIV: a rapid review of safety and efficacy concerns challenging its role in modern ART

Therapeutic Advances in Infectious Disease
Emerging evidence from the REPRIEVE study cohort has further clarified the association between abacavir use and cardiovascular risk. This analysis, along with previous findings, demonstrates a significant elevation in time to first major adverse ...
David B. Cluck, Daniel B. Chastain, Jacob D. Lines, William R. Short, Diego Cecchini, Juan Ambrosioni, Andrés F. Henao-Martínez, Elizabeth M. Sherman   +7 more
doaj   +1 more source

Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir

Nigerian Postgraduate Medical Journal, 2019
Background: The presence of human leukocyte antigen (HLA) B*57:01 allele predicts hypersensitivity reaction (HSR) to abacavir (ABC), a nucleoside reverse-transcriptase inhibitor used for human immunodeficiency virus (HIV) treatment.
Oche O Agbaji, Maxwell O Akanbi, Ihedinachi Otoh, Patricia E Agaba, Rolake Akinsola, Victoria Okolie, Placid O Ugoagwu, Aliyu A Babadoko, Adewumi Adediran, Finomo O Finomo, Jonah O Abah, Haruna M Muktar, Alani S Akanmu   +12 more
doaj   +1 more source

Predictors of Liver Steatosis Progression Among People Living With HIV in Low‐ and Middle‐Income Countries: A Multicentre Longitudinal Study

Journal of the International AIDS Society, Volume 29, Issue 10, October 2026.
ABSTRACT Introduction Liver steatosis is increasingly recognized as a major comorbidity in people living with HIV (PLWH), with growing evidence suggesting an increased risk of progression to advanced liver disease. We assessed predictors of liver steatosis progression over 36 months in PLWH from low‐ and middle‐income countries.
Marie K. Plaisy, Thierry Tiendrebeogo, Carlotta Mondoka, Mark H. Kuniholm, Rodrigo de Carvalho Moreira, Aggrey Semeere, Rohidas T. Borse, Albert Minga, Gilles Wandeler, Gad Murenzi, Brenda E. Crabtree‐Ramírez, Niharika Samala, Jeremy Ross, Ephrem Mensah, Ardele Mandiriri, Sandra W. Cardoso, Jean Paul Mivumbi, Lameck Diero, Haridas Prasad, Paola Alarcón Murra, Belinda V. Chihota, Suzanne Goodrich, Thida Chanyachukul, Ellen Brazier, Stephany N. Duda, Hugo Perazzo, Antoine Jaquet, the International epidemiology Databases to Evaluate AIDS (IeDEA)   +27 more
wiley   +1 more source

Cytokine profiling in abacavir hypersensitivity patients [PDF]

, 2008
BACKGROUND: Abacavir hypersensitivity in genetically susceptible individuals implicates an abacavir-specific T-cell response to either the parent drug or a metabolite generated in vivo. We have analysed the cytokine profile in antigen-presenting cells
Martin, A.M., Nolan, D., Phillips, E., Almeida, C.M., Cameron, P.U., James, I., Lucas, A., Mallal, S.   +7 more
core  

Effects of abacavir on the vascular and platelet activities [PDF]

, 2010
Abacavir is an antiviral nucleoside analogue effectively used to treat HIV infection. However, a study showed that the use of abacavir significantly increased the risks of stroke and myocardial infraction.
Kwan, SYW, Leung, GPH, Li, RWS
core   +1 more source

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

BMC Pharmacology and Toxicology, 2018
Background Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic ...
Julián Olalla, Javier Pérez-Stachowski, Begoña Tortajada, Alfonso Del Arco, Efrén Márquez, Javier De la Torre, Miriam Nieto, José María García de Lomas, José Luis Prada, Javier García-Alegría   +9 more
doaj   +1 more source

Dermatographism Is Common in Drug Allergy Patients, but Does Not Appear to Affect Fluoroquinolone or Vancomycin Skin Testing

Clinical &Experimental Allergy, EarlyView.
Claire Brewer, Rebecca Lee, Matthew Krantz, Elizabeth Phillips, Cosby A. Stone Jr.   +4 more
wiley   +1 more source